Quotables
"There is no reason anyone would want a computer in their home."
Ken Olsen, chairman and founder of Digital Equipment Corporation ; 1977
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7432308 | Therapeutic compositions for the treatment of a respiratory tract disease The equilibrium between G actin and F actin is shifted towards the F actin confirmation with compounds such as the ionic form of magnesium or potassium. The higher amount of F actin decreases the inhibition of nucleases such as DNAse I by monomeric G actin. The incr... | 10/07/2008 |
| 7368104 | Treatment of respiratory diseases A pharmaceutical composition for pulmonary delivery comprises glycopyrrolate in a controlled release formulation, wherein, on administration, the glycopyrrolate exerts its pharmacological effect over a period greater than 12 hours. ... | 05/06/2008 |
| 7335683 | Compositions and methods for cystic fibrosis therapy Compositions and methods for therapy of cystic fibrosis and other conditions are provided. The compositions comprise one or more compounds such as flavones and/or isoflavones capable of stimulating chloride transport in epithelial tissues. Therapeutic methods involv... | 02/26/2008 |
| 7223744 | Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof The present invention provides a method of treating edematous retinal disorders. The method comprises administration of a pharmaceutical formulation comprising a hydrolysis-resistant P2Y receptor agonist to stimulate the removal of pathological extraneous fluid from... | 05/29/2007 |
| 7132410 | Di(uridine 5′-)tetraphosphate and salts thereof The present invention are directed to P1, P4-di(uridine 5′-)tetraphosphate, tetra-alkali metal salts such as tetrasodium, tetralithium, tetrapotassium, and mixed tetra-alkali metal cations thereof. The tetra alkali metal salts of P1 | 11/07/2006 |
| 7087249 | Treatment of mucosal membranes The invention relates to the use of one or more antimicrobial metals preferably selected from silver, gold, platinum, and palladium but most preferably silver, formed with atomic disorder, and preferably in a nanocrystalline form, for reducing inflammation or infect... | 08/08/2006 |
| 7078391 | Method of treating edematous retinal disorders The present invention provides a method of treating edematous retinal disorders. The method comprises administration of a pharmaceutical formulation comprising a hydrolysis-resistant P2Y receptor agonist to stimulate the removal of pathological extraneous fluid from... | 07/18/2006 |
| 7045152 | Treating pulmonary disorders with gaseous agent causing repletion of GSNO Pulmonary disorders in which the GSNO pool or glutathione pool in the lung is depleted and where reactive oxygen species in lung are increased, are treated by delivering into the lung as a gas, agent causing repletion or increase of the GSNO pool or protection again... | 05/16/2006 |
| 6926911 | Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs Chronic obstructive airway diseases are treated by administering an osmotically active compound such as a salt, sugar, sugar alcohol, or organic osmolyte to the afflicted airway surface. The compound may be administered as a liquid or dry powder aerosol formulation.... | 08/09/2005 |
| 6890907 | Methods and unit dose formulations for the inhalation administration of tobramycin A patient suffering from an endobronchial infection is treated by administering to the patient for inhalation a dose of less than about 4.0 ml of a nebulized aerosol formulation comprising from about 60 to about 200 mg/ml of an aminoglycoside antibiotic, such as tob... | 05/10/2005 |
| 6881725 | Method for treating pain The present invention is directed to a method of treating pain. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a P2X receptor antagonist. The methods of the present invention are useful in reducing pain... | 04/19/2005 |
| 6872710 | Di(uridine 5′)-tetraphosphate and salts thereof The present invention is directed to P1, P4-di(uridine 5′)-tetraphosphate, tetra-alkali metal salts such as tetrasodium, tetralithium, tetrapotassium, and mixed tetra-alkali metal cations thereof. The tetra alkali metal salts of P1... | 03/29/2005 |
| 6867199 | Dinucleoside polyphosphate compositions and their therapeutic use The present invention relates to certain novel dinucleoside polyphosphates of general Formulae I, II and III, and formulations thereof which are selective ligands of the P2Y purinergic receptors. Applicants have discovered that dinucleoside polyphosphates of general... | 03/15/2005 |
| 6861449 | Method of treating neutrophil-related diseases with topical anesthetics A therapeutic method is provided to treat neutrophil-associated pulmonary diseases, such as chronic obstructive pulmonary disease, by locally administering to a mammal in need of such treatment, an effective amount of a topical anesthetic, such as lidocaine, or a ph... | 03/01/2005 |
| 6824761 | Anti-asthmatic combinations comprising surface active phospholipids Disclosed is a combination product for use in treating asthma and other respiratory conditions comprising a medicament comprising a surface active phospholipid composition in the form of a fine powder and an antiasthma drug. The product is arranged to be administere... | 11/30/2004 |
| 6818629 | Pharmaceutical formulation comprising P1-(2'-deoxycytidine 5'-)P4-(uridine 5'-) tetraphosphate The present invention provides a method of treating edematous retinal disorders. The method comprises administration of a pharmaceutical formulation comprising a hydrolysis-resistant P2Y receptor agonist to stimulate the removal of pathological extraneous fluid from... | 11/16/2004 |
| 6815432 | Methods for encapsulating plasmids in lipid bilayers Plasmid-lipid particles which are useful for transfection of cells in vitro or in vivo are described. The particles can be formed using either detergent dialysis methods or methods which utilize organic solvents. The particles are typically 65-85 nm, fully encapsula... | 11/09/2004 |
| 6762170 | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives There are provided according to the invention, novel compounds of formula (I) wherein R1, R2 and R3 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the tr... | 07/13/2004 |
| 6703376 | Use of uridine triphosphates and related compounds for the prevention and treatment of pneumonia in immobilized patients A method of promoting drainage of mucous secretions in the congested airways of a bedridden/immobilized patient or an intubated/mechanically-ventilated patient is disclosed. The method comprises administering to the airways of the patient a uridine phosph... | 03/09/2004 |
| 6702998 | Methods and devices for treating lung dysfunction Methods and devices useful for treatment of lung conditions resulting from dysfunction of normal pulmonary physiology.... | 03/09/2004 |
| 6670394 | Method for treating COPD This invention relates to a method for the prophylaxis of or for treating COPD by administering a PDE4 inhibitor which has a defined therapeutic ratio.... | 12/30/2003 |
| 6596770 | Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor The present invention provides a novel dithiocarbamamte disulfide dimer useful in various therapeutic treatments, either alone or in combination with other active agents. In one method, the disulfide derivative of a dithiocarbamate is coadministered with ... | 07/22/2003 |
| 6596745 | Method for treating fibrotic diseases with azolium chroman compounds Provided is a method of treating or ameliorating hypertension in an animal comprising administering an effective amount of a compound of formula I: ##STR1##... | 07/22/2003 |
| 6576669 | Use of an LTB4 antagonist for the treatment or prevention of diseases caused by increased expression of mucin genes Medicaments and pharmaceutical kits comprising an LTB4 antagonist of formula (I) ##STR1## a tautomer thereof or a pharmaceutically acceptable salt thereof, and methods of treating or preventing cystic fibrosis, diseases caused by increased... | 06/10/2003 |
| 6576654 | Method for the treatment of cystic fibrosis A method is disclosed for the treatment of cystic fibrosis by administering to a human in need thereof a therapeutically effective amount of an sPLA2 inhibitor, such as a 1H-indole-3-glyoxylamide.... | 06/10/2003 |
| 6537968 | Treatment of lupus erythematosus The present invention provides for the treatment of an individual suffering from lupus erythematosus utilizing a serine protease inhibitor. The treatment includes the use of a corticosteroid that is administered separately or in combination. The serine pr... | 03/25/2003 |
| 6537550 | Use of avian antibodies The present invention relates to use of avian antibodies and/or antigen binding fragments thereof, for the production of a drug for treatment and/or prevention of respiratory tract infection. The drug is administered through local application at the oral ... | 03/25/2003 |
| 6534486 | 2-(purin-9-yl)-Tetrahydrofuran-3,4-diol derivatives A series of 2-(Purin-9-yl)-tetrahydrofuran-3,4-diol derivatives with broad anti-inflammatory properties which inhibit leukocyte recruitment and activation and which are agonists of the adenosine 2a receptor are described.... | 03/18/2003 |
| 6534484 | Methods for encapsulating plasmids in lipid bilayers Plasmid-lipid particles which are useful for transfection of cells in vitro or in vivo are described. The particles can be formed using either detergent dialysis methods or methods which utilize organic solvents. The particles are typically 65-85 nm, full... | 03/18/2003 |
| 6528494 | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives There are provided according to the invention novel compounds of formula I ##STR1## wherein R1, R2 and R3 are as described in the specification, processes for preparing them, formulations containing them and their use in t... | 03/04/2003 |
| 6506377 | Interferon-alpha mediated upregulation of aquaporin expression A method for enhancing the expression of aquaporin proteins by contacting aquaporin producing cells with interferon- is described. The method enables treatment of patients afflicted with disease states characterized by xerosis.... | 01/14/2003 |
| 6503945 | Cationic amphiphiles containing N-hydroxyalkyl group for intracellular delivery of biologically active molecules The present invention provides novel cationic amphiphiles containing novel N-hydroxyalkyl group and therapeutic formulations containing the said amphiphiles that are capable of facilitating transport of biologically active molecules into cells. The said n... | 01/07/2003 |
| 6497877 | Plasminogen activator as an anti-inflammatory agent Plasminogen activator acts as an anti-inflammatory agent by inhibiting generation of superoxide anion by a mechanism that is not related to L-arginine, is not dependent on thrombolytic activity, and is not a function of oxygen free radical scavenging. Mor... | 12/24/2002 |
| 6465494 | Methods for treatment of cystic fibrosis Substituted condensation products of N-benzyl-3-indenylacetamides with heterocyclic aldehydes and other such inhibitors are useful for the treatment of cystic fibrosis.... | 10/15/2002 |
| 6451288 | Method of treating lung diseases with uridine 5'-diphosphate and analogs thereof Compounds of Formula I: ##STR1## wherein: X1, and X2 are each independently either O- or S- ; X3 and X4 are each independently either --H or --OH, with the proviso that X3 and X4... | 09/17/2002 |
| 6436443 | Porous particles comprising excipients for deep lung delivery Improved porous particles for drug delivery to the pulmonary system, and methods for their synthesis and administration are provided. In a preferred embodiment, the porous particles are made of a biodegradable material and have a mass density less than 0.... | 08/20/2002 |
| 6426337 | 2-(Purin-9-yl)-tetrahydrofuran-3,4-diol derivatives There are provided according to the invention novel compounds of formula (I) wherein R1, R2, and R3 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy... | 07/30/2002 |
| 6350467 | Pharmaceutical preparations of glutathione and methods of administration thereof A method of increasing glutathione levels in mammalian cells comprising administering an oral bolus of encapsulated pharmaceutically stabilized glutathione in a rapidly dissolving formulation to a mammal on an empty stomach. Pharmaceutical formulations in... | 02/26/2002 |
| 6346516 | Cationic amphiphiles containing N-hydroxyalkyl group for intracellular delivery of biologically active molecules The present invention provides novel cationic amphiphiles containing novel N-hydroxyalkyl group and therapeutic formulations containing the said amphiphiles that are capable of facilitating transport of biologically active molecules into cells. The said n... | 02/12/2002 |
| 6344475 | Conductance of improperly folded proteins through the secretory pathway This invention provides the methodology and agents for treating any disease or clinical condition which is at least partly the result of endoplasmic reticulum-associated retention of proteins. Thus, the methods and agents of the present invention provide ... | 02/05/2002 |
